Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Prepaid Assets: 2009-2025

Historic Prepaid Assets for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to $13.0 million.

  • Cytokinetics' Prepaid Assets rose 95.14% to $13.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.0 million, marking a year-over-year increase of 95.14%. This contributed to the annual value of $15.3 million for FY2024, which is 27.90% up from last year.
  • Per Cytokinetics' latest filing, its Prepaid Assets stood at $13.0 million for Q3 2025, which was down 34.96% from $20.0 million recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Prepaid Assets registered a high of $20.0 million during Q2 2025, and its lowest value of $3.0 million during Q1 2021.
  • In the last 3 years, Cytokinetics' Prepaid Assets had a median value of $15.7 million in 2023 and averaged $15.3 million.
  • In the last 5 years, Cytokinetics' Prepaid Assets surged by 423.44% in 2021 and then tumbled by 66.13% in 2024.
  • Cytokinetics' Prepaid Assets (Quarterly) stood at $12.2 million in 2021, then rose by 2.02% to $12.5 million in 2022, then declined by 4.16% to $11.9 million in 2023, then climbed by 27.90% to $15.3 million in 2024, then spiked by 95.14% to $13.0 million in 2025.
  • Its Prepaid Assets was $13.0 million in Q3 2025, compared to $20.0 million in Q2 2025 and $15.8 million in Q1 2025.